Karuna Therapeutics Inc (NASDAQ:KRTX)

192.24
Delayed Data
As of Feb 06
 +0.16 / +0.08%
Today’s Change
92.26
Today|||52-Week Range
278.25
-2.17%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$6.6B

Company Description

Karuna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. engages in business of research and development of therapies utilizing muscarinic cholinergic receptors to treat psychosis and cognitive impairment in numerous central nervous system disorders. The company was founded by Andrew Miller, Eric Elenko, and Peter Jeffrey Conn in July 2009 and is headquartered in Boston, MA.

Contact Information

Karuna Therapeutics, Inc.
99 High Street
Boston Massachusetts 02110
P:(857) 449-2244
Investor Relations:
(518) 338-8990

Employees

Shareholders

Mutual fund holders52.94%
Other institutional31.84%
Individual stakeholders30.70%

Top Executives

William J. MeuryPresident, Chief Executive Officer & Director
Andrew MillerChief Operating Officer
Troy A. IgnelziChief Financial Officer & Secretary
Stephen BrannanChief Medical Officer
Steven Marc PaulDirector, Chief Scientific Officer, President-R&D